外周细胞淋巴瘤诊疗进展.pptVIP

Anti-CD30ADC:BrentuximabVedotin(SGN-35)ADC:3partsChimericantibodySGN-30Syntheticanalogue(MMAE)oftheantitubulinagentdolastatin10StabledruglinkerProposedmechanismofactionBindstoCD30InternalizedintothetumorcellMMAEisreleasedTumorcellundergoesG2/Mphasecell-cyclearrestandapoptosisPreclinicalactivityobservedbothininvitroandinvivoFranciscoJA,etal.Blood.2003;102:1458-1465.第31页，共49页，星期日，2025年，2月5日BrentuximabVedotin+化疗一线治疗ALCLI期临床试验:39pts高危ALCL(IPI≥2)orCD30+成熟

T-cell/NK-细胞淋巴瘤随机分为3组1.8mg/kgbrentuximabvedotinq3wX2cycles,thenCHOPx6cycles1.8mg/kgbrentuximabvedotin+CHPq3wforupto6cyclesDetermineoptimaldoseofbrentuximabvedotintobeusedincombinationwithCHPinthirdarmRespondersreceiveadditionalcyclesofbrentuximabvedotinmonotherapyORR:100%(26/26);CR:88%(23/26)BrentuximabvedotinMTDnotexceededat1.8mg/kg1DLT:grade3rashin6pts治疗相关并发症:恶心(58%),疲乏(50%),腹泻(50%),周围神经病变(38%),脱发(38%)FanaleMA,etal.ASH2012.Abstract60.第32页，共49页，星期日，2025年，2月5日ProB,etal.JClinOncol.2012;30:2190-2196.BrentuximabVedotininRel/RefSystemicALCL:MaximumTumorReduction(IRC)TumorSize(%change

frombaseline)-100-50050100IndividualPatients(n=57)BestclinicalresponseCompleteremissionPartialremission

Stabledisease

ProgressivediseaseHistologicallyineligible第33页，共49页，星期日，2025年，2月5日DueckG,etal.Cancer.2010;116:4541-4548.来啦度胺II期临床试验：24PTCLPts.（N=24）ORR:30%(7/23)AllPRs 所有亚型都有效MedianPFS:96days MedianOS:241days AEs:中性粒细胞减少、疼痛、血小板减少、皮疹第34页，共49页，星期日，2025年，2月5日Interimreportofaphase2clinicaltrialoflenalidomideforT-cellnon-HodgkinlymphomaRelapsed/refractoryPTCLECOGPS0-2(N=24)Lenalidomide25mgPOqdon

Days1-21ofa28daycycleTheprimaryendpoint；ORR?Thesecondaryendpoints:OS,PFS,andsafety.open-label,single-arm,multicenterCanadianphase2clinicaltrial?September